雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

A case of metastatic choroidal tumor successfully treated with selpercatinib Chisato Horitani 1 , Ryuto Nishisho 1 , Masashi Kimura 1 , Tomoko Kawamura 1 , Youhei Kimura 2 , Masumi Tanabe 1 1Department of Ophthalmology, Harima-Himeji General Medical Center 2Department of Respiratory medicine, Harima-Himeji General Medical Center pp.749-755
Published Date 2024/6/15
DOI https://doi.org/10.11477/mf.1410215201
  • Abstract
  • Look Inside
  • Reference

Abstract Introduction:Oncogenic rearranged during transfection(RET)gene fusions are rare mutations that are found in 2% of non-small cell lung cancers(NSCLC). In September 2021, selpercatinib, a tyrosine kinase inhibitor, was approved in Japan for RET fusion-positive NSCLC. We report a case of RET fusion gene-positive lung adenocarcinoma in which a metastatic choroidal tumor was significantly reduced with selpercatinib treatment.

Case presentation:A 49-old-female patient presented with decreased visual acuity in the left eye for 2 weeks. She was diagnosed with left choroidal metastasis at an eye clinic and referred to our department.

Findings:Her best-corrected visual acuity was 20/20 in the right eye, and 20/25 in the left eye. Fundus examination revealed subretinal lesions located above the macula. Computed tomography(CT)scans of the chest showed a pulmonary nodule in the left lobe and mediastinal lymphadenopathy. She was diagnosed with pathological stage ⅣB lung adenocarcinoma(T1bN3M1c), received chemotherapy using cisplatin, pemetrexed, and pembrolizumab. After four cycles of chemotherapy, she was switched to maintenance therapy with single agent pembrolizumab due to adverse effects. Despite switching treatment, after 7 months, tumors in the choroidal metastasis and primary lesion showed no improvement. During treatment, the patient was identified as RET fusion gene-positive. After 2 weeks of RET-targeted therapy, OCT revealed a significant response for choroidal metastasis.

Conclusion:We report a case of a patient with NSCLC with choroidal metastasis. The patient showed a good response to selpercatinib. The progress of the choroidal metastasis should be used to determine the effectiveness of treatment.


Copyright © 2024, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1882-1308 印刷版ISSN 0370-5579 医学書院

関連文献

もっと見る

文献を共有